ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression

The successful treatment of patients with advanced non–small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) with ALK tyrosine kinase inhibitors (ALK-TKIs) represents a promising targeted therapy. As a result, various ALK-TKIs have been rapidly devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wen, Yu, Danlei, Zhai, Yifan, Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199254/
https://www.ncbi.nlm.nih.gov/pubmed/37192591
http://dx.doi.org/10.1016/j.neo.2023.100908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199254/
https://www.ncbi.nlm.nih.gov/pubmed/37192591
http://dx.doi.org/10.1016/j.neo.2023.100908

Ejemplares similares